Adoptive immunotherapy using receptor engineering to achieve specific tumor targeting by T cells holds much promise for advancing cancer therapy. Here, two studies by Boice et al. and Roybal et al. provide distinct and potentially complimentary approaches to improve the efficacy and curb potential toxicities of this approach.
Adoptive immunotherapy using T cells genetically redirected with antigen receptors enabling the recognition and destruction of cancer cells is poised to enter mainstream clinical practice. However, concerns over the safety and potency of current T cell therapies persist (Klebanoff et al., 2016) . In this issue of Cell, Boice et al. (2016) and Roybal et al. (2016) offer distinct and potentially complimentary approaches to enhance the antitumor functions of T cells modified with chimeric antigen receptors (CARs) (Boice et al., 2016 , Roybal et al., 2016 . In both cases, the authors combined a mechanistic understanding of signaling networks in normal and transformed cells with creativity and ingenuity to engineer T cells capable of functioning as ''micro-pharmacies.'' Somatic mutations and chromosomal deletions involving the tumor necrosis factor receptor superfamily member herpesvirus entry mediator (HVEM) are among the most common genetic lesions in human B cell lymphomas (Morin et al., 2011) . However, whether loss of HVEM function directly contributes to lymphomagenesis was previously unknown. Although HVEM has several binding partners, the majority of mutations in the receptor occur throughout its extracellular domain in a region critical for binding to the co-inhibitory receptors B-and T-lymphocyte attenuator (BTLA) and CD160. Because BTLA, but not CD160, is expressed on both normal and malignant B cells, Boice et al. (2016) conjectured that disruption of the HVEM-BTLA axis might contribute to B cell transformation.
To test this hypothesis, the authors used the well-established VavP-Bcl2 murine lymphoma model. In this system, BCL2 is constitutively expressed in cells of hematopoietic origin, a phenomenon common to many B cell lymphomas in humans. Using short hairpin RNAs to attenuate HVEM expression in hematopoietic progenitor cells taken from VavP-Bcl2 transgenic mice, the authors observed a significant increase in the frequency of lymphoma formation compared with empty vector controls. Reporter expression for the hairpin construct was exclusively enriched within the B cell compartment, supporting a model whereby a B-cell-intrinsic defect in HVEM was responsible for accelerated transformation. Finally, increased mitogenic signals arising from dysregulated B cell receptor activation were found in HVEM-deficient lymphomas, a finding consistent with impaired BTLA signaling. Based on these data, Boice et al. (2016) conclude that HVEM serves as a tumor suppressor in B cells and that its loss drives B cell expansion and ultimately lymphoma formation.
Because BTLA is rarely mutated in cancer, the authors tested whether reconstitution of BTLA signaling using a recombinant soluble version of HVEM (solHVEM) could treat lymphomas harboring mutated HVEM. Although intra-tumoral injection of solHVEM caused a marked delay in xenograft lymphoma growth, systemic administration did not. To overcome this limitation, the authors designed a potentially translatable means of delivering high local concentrations of sol-HVEM to lymphomas in vivo. They constructed a multicistronic retroviral vector that constitutively co-expresses solHVEM in tandem with an anti-CD19 CAR currently used in late-stage clinical trials (Davila et al., 2014) . With this approach, they found that CAR-mediated lymphoma destruction was measurably enhanced with incorporation of the solHVEM payload in the absence of overt toxicity to recipient mice. Importantly, although HVEM can function as a negative regulator of some T cell subsets, this potential effect did not compromise treatment efficacy. Thus, solHVEM now joins other soluble mediators, including interleukin (IL)-12 (Kerkar et al., 2010; Pegram et al., 2012) and IL-15 (Klebanoff et al., 2004) , as candidate factors that might be constitutively expressed by transferred T cells to enhance antitumor immunity. However, what if the desired payload was far more noxious than solHVEM?
In a separate manuscript, Roybal et al. (2016) offer a potential solution to the challenge of safely delivering toxic payloads or targeting high-risk antigens using a modular synthetic receptor based on the Notch receptor. Whereas a secondgeneration CAR design common to most receptors in clinical development coopts endogenous signaling pathways associated with T cell activation, the synNotch receptor does not (Figure 1 ). synNotch activation leads to the intracellular liberation of a synthetic transcription factor that works entirely independently of the normal transcriptional machinery that is present within a T cell. This is accomplished by repurposing a transcription factor network present in yeast to selectively drive gene expression. In this manner, a user can have complete control over when and how a T cell responds to given stimuli, including reprogramming a T cell to produce antibodies like B cells.
Despite its elegance, the synNotch receptor, as presently configured, has certain limitations that could complicate its clinical development. For example, the construct makes use of a Notch core region taken from mice and a yeastderived transcriptional regulator. Even in immunocompromised patients, expression of transgenes encoding novel proteins can be immunogenic, leading to T-cell-mediated rejection and loss of persistence of the modified cells (Riddell et al., 1996) . Indeed, the cell therapy field is rapidly moving to employ only human or humanized segments into CAR designs, precisely because of immunogenicity concerns (Klebanoff et al., 2016) . Exchange of the murine-derived regions for the corresponding human sequence is straightforward. However, replacement of the transcriptional output to a human sequence will be more challenging because of the requirement that it function orthogonally to any other transcriptional network operative in T cells. One solution could be incorporation of a wholly synthetic transcription factor system based on artificial zinc fingers derived in part from human sequences and that bind to modular DNA-binding domains (Khalil et al., 2012) . Alternatively, a fully human transcription factor network exclusive to other human cell types, such as neurons or endocrine cells, but absent in T cells might be used. In either case, confirmation that these new transcription factor networks function orthogonally and are not immunogenic will be essential. Overriding all of these concerns is the essential problem challenging the entire field, which is the scarcity of truly tumor-specific targets on most solid cancers for which CAR T cells might be safely redirected (Klebanoff et al., 2016) . Regardless, both papers make important inroads and further expand the toolkit available to the practicing cell therapist. Next-generation immunotherapies incorporating conditional receptors and new payload delivery systems are on the horizon with the exciting promise to enhance potency while simultaneously improving safety.
In this issue of Cell, Lu et al. provide important insights on the efficacy of human antibodies to Mycobacterium tuberculosis and on how functional heterogeneity of the antibody response may explain a century of contradictory evidence for the role of humoral immunity in defense against tuberculosis.
At the dawn of immunology there was a colossal debate between proponents of humoral and cellular immunity as to the relative importance of the two immune arms (Silverstein, 1979) . The humoral school championed antibody as the mediator of immunity, while the cellular school championed phagocytic cells as the key mediator of host defense, with antibody being an auxiliary component relegated primarily to promoting opsonization. By the early decades of the 20th century, the humoralist's view prevailed, but there were problems with the theory: some hosts had specific antibody but were susceptible, and it was difficult to prove the importance of antibody by passive transfer experiments against certain microbes, including a very important human pathogen, the Mycobacterium tuberculosis (Mtb) bacterium. Since the 1890s, many studies suggested that humoral immunity protected against tuberculosis with inconsistent results (Glatman-Freedman and Casadevall, 1998) . By the 1940s, the phagocytic theory was reformulated as tissue immunity which posited that granuloma formation protected against those microbes for which it was difficult to show the efficacy of humoral immunity, including intracellular bacterial pathogens and fungi. Hence, universal views of immunity were replaced with sectarian views that assigned responsibility for protection to different arms of the immune system, a paradigm that persisted into the 1990s (Figure 1) .
A role for humoral immunity in host defense against a microbe is established by: (1) passive antibody experiments that confer protection; (2) an association between serum antibodies and resistance to infection; and (3) an association between disease and humoral immunodeficiency. In the case of Mtb, these criteria have provided inconsistent evidence for a role for antibodies in host defense (Achkar and Casadevall, 2013) . Passive protection experiments showed protection in some cases, but not others, brisk antibody responses occurred in diseased individuals, and there has been no obvious association between tuberculosis and humoral immunodeficiency. On the other hand, host defense against mycobacteria is associated with granuloma formation, which is representative of cellular immunity, and T cell defects are associated with severe disease. However, often forgotten in the debate was the fact that these criteria are informative only when the result is positive since negative effects do not exclude the possibility that protective Ab responses exist. Similarly, the absence of cases in association with
